Physician profile
James Kerrigan
NPI 1811971997
$853.61
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $190 · 2021: $364.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Asahi Intecc USA, INC. | $187.05 | 2019-2020 | |
| Shockwave Medical, INC | $170.04 | 2021 | |
| Verge Medical, INC. | $147.76 | 2021 | |
| Inari Medical, INC. | $113.26 | 2020 | |
| Abbott Laboratories | $100.90 | 2019 | |
| Becton, Dickinson and Company | $46.67 | 2021 | |
| Medtronic Minimed, INC. | $26.88 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $18.66 | 2019 | |
| Abbvie INC. | $16.39 | 2019 | |
| Tandem Diabetes Care, INC. | $13.01 | 2019 | |
| Lilly USA, LLC | $12.99 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kerrigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.